First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
A phase 1/2 trial of DS-3939a in advanced solid tumours, run by Daiichi Sankyo, now recruiting.
Overview
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05875168 by Daiichi Sankyo, with 590 participants planned, started 2023-08-18 and due to reach its primary completion in 2026-10-20. Interventions recorded: DS-3939a.
Similar pages
not linked directly; found by shared links- TrialSubstudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Shares Daiichi Sankyo, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Shares Daiichi Sankyo, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Shares Daiichi Sankyo, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Shares Daiichi Sankyo, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Shares Daiichi Sankyo, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Shares Daiichi Sankyo, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Shares Daiichi Sankyo, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
Shares Daiichi Sankyo, Metastatic cancer (cancer that has spread) and the tag pipeline.